UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

UMN Pharma Inc. today announced initiation of phase I/II clinical trials in human subjects with UMN-0501, UMN's pandemic influenza vaccine. In Japan, this is the "first-in-man" clinical study of a pandemic influenza vaccine manufactured by cell-culture. The purpose of this clinical study is to assess safety and efficacy in 125 healthy adults aged 20-40. Study results will be obtained by the end of the year.